Editorial Board
(Source: Leukemia Research)
Source: Leukemia Research - March 20, 2018 Category: Hematology Source Type: research
High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype
A complex karyotype (CK) is found in the bone marrow cells of 10 –12% of patients with acute myeloid leukemia (AML) at the initial cytogenetic evaluation [1]. The incidence increases with the age of the patient [1,2]. CK has been variably defined as harboring at least five abnormalities in different studies [3–6]. CK is traditionally regarded as a poor progno stic factor, and it is strongly associated with poor outcomes particularly in patients showing more than five changes in bone marrow cells [7,8]. (Source: Leukemia Research)
Source: Leukemia Research - March 19, 2018 Category: Hematology Authors: Iveta Sarova, Jana Brezinova, Zuzana Zemanova, Sarka Ransdorfova, Karla Svobodova, Silvia Izakova, Lenka Pavlistova, Libuse Lizcova, Adela Berkova, Karolina Skipalova, Lucie Hodanova, Cyril Salek, Anna Jonasova, Kyra Michalova Tags: Research paper Source Type: research
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55 –65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
The results of the treatment of Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in adults have improved in recent years [1]. The use of pediatric-like protocols in the younger adult (YA) population partially explains this improvement. Intensified pediatric-inspired regimens with continuous dose-intense exposure to chemotherapy and higher cumulative doses of non-myelotoxic drugs such as L-asparaginase and glucocorticoids are currently used by most groups to treat ALL in adult patients [2,3]. (Source: Leukemia Research)
Source: Leukemia Research - March 19, 2018 Category: Hematology Authors: Josep-Maria Ribera, Olga Garc ía, Cristina Gil, Santiago Mercadal, Irene García-Cadenas, Pau Montesinos, Pere Barba, Susana Vives, José González-Campos, Mar Tormo, Jordi Esteve, Aurelio López, María José Moreno, Jordi Ribera, Natalia Alonso, Aranch Tags: Research paper Source Type: research
High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype
(Source: Leukemia Research)
Source: Leukemia Research - March 19, 2018 Category: Hematology Authors: Iveta Sarova, Jana Brezinova, Zuzana Zemanova, Sarka Ransdorfova, Karla Svobodova, Silvia Izakova, Lenka Pavlistova, Libuse Lizcova, Adela Berkova, Karolina Skipalova, Lucie Hodanova, Cyril Salek, Anna Jonasova, Kyra Michalova Tags: Research paper Source Type: research
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
(Source: Leukemia Research)
Source: Leukemia Research - March 19, 2018 Category: Hematology Authors: Josep-Maria Ribera, Olga Garc ía, Cristina Gil, Santiago Mercadal, Irene García-Cadenas, Pau Montesinos, Pere Barba, Susana Vives, José González-Campos, Mar Tormo, Jordi Esteve, Aurelio López, María José Moreno, Jordi Ribera, Natalia Alonso, Aranch Tags: Research paper Source Type: research
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
Multiple myeloma (MM) is one of the most common hematological malignancies. It newly affects approximately 21,500 patients (pts) each year in Europe with 15,000 dying from this disease annually [1]. Although, the currently used first-line therapies induce remissions in the majority of pts, relapses are expected to occur in almost all. (Source: Leukemia Research)
Source: Leukemia Research - March 14, 2018 Category: Hematology Authors: Wolfgang Knauf, Ali Aldaoud, Christoph Losem, Johann Mittermueller, Michael Neise, Beate Niemeier, Johanna Harde, Tanja Trarbach, Karin Potthoff Tags: Research paper Source Type: research
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
(Source: Leukemia Research)
Source: Leukemia Research - March 14, 2018 Category: Hematology Authors: Wolfgang Knauf, Ali Aldaoud, Christoph Losem, Johann Mittermueller, Michael Neise, Beate Niemeier, Johanna Harde, Tanja Trarbach, Karin Potthoff Tags: Research paper Source Type: research
Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS
Myelodysplastic syndromes (MDS) are a group of heterogeneous oligoclonal stem cell disorders characterized by peripheral cytopenia and a risk of transformation into acute myeloid leukemia (AML). Anemia is the most frequent symptom and reflects the impaired erythroid cell maturation. (Source: Leukemia Research)
Source: Leukemia Research - March 10, 2018 Category: Hematology Authors: Tobias Boch, Thomas Luft, Georgia Metzgeroth, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, Franziska La Meir, Christiane Schumann, Jennifer Klemmer, Susanne Brendel, Harald Fricke, Claudia Kunz, Christel Wei ß, Wolf-Karsten Hofmann, Florian N Tags: Research paper Source Type: research
Safety and Efficacy of the CD95 - Ligand Inhibitor Asunercept in Transfusion - Dependent Patients with Low and Intermediate Risk MDS
(Source: Leukemia Research)
Source: Leukemia Research - March 10, 2018 Category: Hematology Authors: Tobias Boch, Thomas Luft, Georgia Metzgeroth, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, Franziska La Meir, Christiane Schumann, Jennifer Klemmer, Susanne Brendel, Harald Fricke, Claudia Kunz, Christel Wei ß, Wolf-Karsten Hofmann, Florian N Tags: Research paper Source Type: research
Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common adult acute leukemia with 21,380 estimated new cases and 10,590 estimated deaths in 2017 [1]. For newly diagnosed AML patients, less than 60 years old, induction chemotherapy with infusional standard-dose cytarabine for 7 days plus an anthracycline (either idarubicin or daunorubicin) for 3 days is a National Comprehensive Cancer Network (NCCN) category 1 recommendation and is the standard of care for the last 30 years [2]. Memorial Sloan Kettering Cancer Center uses either idarubicin (IDA) or daunorubicin for th e treatment of AML, the doses of daunorubicin are either 60...
Source: Leukemia Research - March 8, 2018 Category: Hematology Authors: Amanda N. Seddon, Joshua Chaim, Oguz Akin, Esther Drill, Angela G. Michael, Nelly Adel, Martin S. Tallman Tags: Research paper Source Type: research
Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia
FMS-like tyrosine kinase 3 (FLT3) gene mutations are found in approximately 30% of newly diagnosed acute myeloid leukemia (AML) patients; internal tandem duplication (ITD) mutations in the juxtamembrane domain of FLT3 account for two-thirds of FLT3 mutations. Patients with FLT3-ITD mutations have a poor prognosis, with shorter remission duration and higher relapse rates than FLT3 wild-type AML patients. Although several tyrosine kinase inhibitors (TKIs) targeting FLT3 improve clinical outcomes of FLT3-ITD-mutated AML, the median survival time of these patients is approximately 1 year. (Source: Leukemia Research)
Source: Leukemia Research - March 8, 2018 Category: Hematology Authors: Eun-Ji Choi, Je-Hwan Lee, Jung-Hee Lee, Han-Seung Park, Sun-Hye Ko, Eun-Hye Hur, Juhyun Moon, Bon-Kwan Goo, Yeonhee Kim, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Kyoo-Hyung Lee Tags: Research paper Source Type: research
Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia
(Source: Leukemia Research)
Source: Leukemia Research - March 8, 2018 Category: Hematology Authors: Amanda N. Seddon, Joshua Chaim, Oguz Akin, Esther Drill, Angela G. Michael, Nelly Adel, Martin S. Tallman Tags: Research paper Source Type: research
Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia
(Source: Leukemia Research)
Source: Leukemia Research - March 8, 2018 Category: Hematology Authors: Eun-Ji Choi, Je-Hwan Lee, Jung-Hee Lee, Han-Seung Park, Sun-Hye Ko, Eun-Hye Hur, Juhyun Moon, Bon-Kwan Goo, Yeonhee Kim, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Kyoo-Hyung Lee Tags: Research paper Source Type: research
Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk
Successful acute myeloid leukemia (AML) induction chemotherapy reduces leukemic cells, restores normal hematopoiesis, and results in complete remission (CR) [1], which is associated with improved prognosis [2,3]. Many induction strategies exist, but for over 40 years the cytarabine/anthracycline regimen has been considered standard (so-called 7 + 3) [4]. The best outcomes occur in younger patients with adequate performance status and favorable risk leukemia. In contrast, older patients (≥60 years) and those with adverse prognostic markers fare poorly [5]. (Source: Leukemia Research)
Source: Leukemia Research - March 6, 2018 Category: Hematology Authors: Martin W. Schoen, Susan K. Woelich, James T. Braun, Dhinesh V. Reddy, Mark J. Fesler, Paul J. Petruska, Carl E. Freter, Jack M. Lionberger Tags: Research paper Source Type: research
